author-photo

Kang Sun

Incyte

14

Papers

735

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

312 Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: 104-Week Data From a Phase 2 Study

2021 Journal of Investigative Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
208 Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

2021 Journal of Investigative Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy of Ruxolitinib Cream in Vitiligo by Patient Characteristics and Affected Body Areas: Descriptive Subgroup Analyses From a Phase 2, Randomized, Double-Blind Trial

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (1)
Disease Characteristics and Burden in Patients With Atopic Dermatitis: Insights From Two Phase 3 Studies of Ruxolitinib Cream

2021 The Journal of Allergy and Clinical Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Ruxolitinib Cream for the Treatment of Patients With Alopecia Areata: A 2-Part, Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study

2019 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (10)
Treatment of Atopic Dermatitis With Ruxolitinib Cream (JAK1/JAK2 Inhibitor) or Triamcinolone Cream

2019 The Journal of Allergy and Clinical Immunology
Show All
- Source
- Cite
- Save
Citations (61)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

2017 Journal of Hematology & Oncology
Show All
- Source
- Cite
- Save
Citations (204)
Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

2015 Blood
Show All
- Source
- Cite
- Save
Citations (9)
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

2015 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (162)